Baseline characteristics
| Median age (y) at treatment start (range) | 73 (52-87) | |
| Sex | Number (%) | |
| Male | 25 (60) | |
| Female | 17 (40) | |
| ECOG PS score | ||
| 0 | 23 (55) | |
| 1 | 16 (38) | |
| 2 | 3 (7) | |
| Genetics | ||
| Del(17p)/TP53 aberration | 12 (28) | |
| Del(11q) | 6 (14) | |
| Trisomy 12 | 7 (17) | |
| Normal | 2 (5) | |
| Del(13q) | 8 (19) | |
| Missing | 7 (17) | |
| Treatment line | ||
| First line | 18 (43) | |
| Second line | 14 (33) | |
| Later line | 10 (24) | |
| Type of treatment | ||
| Zanubrutinib | 16 (38) | |
| Ibrutinib | 10 (24) | |
| R-bendamustine | 5 (12) | |
| Ob-ibrutinib | 4 (10) | |
| R-bendamustine + ibrutinib | 3 (7) | |
| Of-idelalisib | 2 (5) | |
| Acalabrutinib | 1 (2) | |
| Ob-chlorambucil | 1 (2) |
| Median age (y) at treatment start (range) | 73 (52-87) | |
| Sex | Number (%) | |
| Male | 25 (60) | |
| Female | 17 (40) | |
| ECOG PS score | ||
| 0 | 23 (55) | |
| 1 | 16 (38) | |
| 2 | 3 (7) | |
| Genetics | ||
| Del(17p)/TP53 aberration | 12 (28) | |
| Del(11q) | 6 (14) | |
| Trisomy 12 | 7 (17) | |
| Normal | 2 (5) | |
| Del(13q) | 8 (19) | |
| Missing | 7 (17) | |
| Treatment line | ||
| First line | 18 (43) | |
| Second line | 14 (33) | |
| Later line | 10 (24) | |
| Type of treatment | ||
| Zanubrutinib | 16 (38) | |
| Ibrutinib | 10 (24) | |
| R-bendamustine | 5 (12) | |
| Ob-ibrutinib | 4 (10) | |
| R-bendamustine + ibrutinib | 3 (7) | |
| Of-idelalisib | 2 (5) | |
| Acalabrutinib | 1 (2) | |
| Ob-chlorambucil | 1 (2) |
ECOG PS, Eastern Cooperative Oncology Group performance status; R, rituximab; Ob, obinutuzumab; Of, ofatumumab.